Literature DB >> 7682232

The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2.

K H Grabstein1, C R Maliszewski, K Shanebeck, T A Sato, M K Spriggs, W C Fanslow, R J Armitage.   

Abstract

Our study demonstrates the central role for the murine CD40 ligand and IL-2 in contact-dependent T cell help for Ag-specific primary antibody responses in vitro. Helper T cell clones were found to express CD40 ligand after activation with CD3 mAb. Membrane-bound recombinant CD40 ligand expressed on fixed CV1/EBNA cells had similar B cell-activating properties as T cell clones that had been activated and then fixed. These activities include the induction of B cell proliferation, induction of polyclonal secretion of multiple Ig isotypes in a cytokine-dependent manner, and induction of Ag-specific antibody responses by purified B cells. The induction of polyclonal Ig secretion by the recombinant CD40 ligand required IL-4 and IL-5 although optimal Ag-specific antibody formation required IL-2. Finally, soluble CD40.Fc inhibited the induction of Ag-specific antibody responses by fixed, activated Th cell clones. The requirement for both CD40 ligand and IL-2 for induction of Ag-specific antibody responses was mediated, in part, by the induction of B cell IL-2R expression by CD40 ligand. We conclude that the interaction of CD40 on B cells with its ligand on activated T cells is an integral event in the early activation of B cells to grow and differentiate to antibody formation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682232

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Authors:  Loren D Erickson; Brigit G Durell; Laura A Vogel; Brian P O'Connor; Marilia Cascalho; Teruhito Yasui; Hitoshi Kikutani; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Naive T-cell receptor transgenic T cells help memory B cells produce antibody.

Authors:  Darragh Duffy; Chun-Ping Yang; Andrew Heath; Paul Garside; Eric B Bell
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

4.  Production of immunoglobulins by human sIgD+ and sIgD- human blood B lymphocytes in response to stimulation with activated T cells and agonistic antibodies; effect of IL-10, IL-2 and mode of activation of T cells.

Authors:  N R Ling; B Brown; D Hardie
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Murine B1 B cells require IL-5 for optimal T cell-dependent activation.

Authors:  L D Erickson; T M Foy; T J Waldschmidt
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

Review 6.  The immune system in the elderly: I. Specific humoral immunity.

Authors:  L Ginaldi; M De Martinis; A D'Ostilio; L Marini; M F Loreto; M P Corsi; D Quaglino
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

7.  Multiple cytokines sharing the common receptor gamma chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway.

Authors:  J D Fayen
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

8.  Enhancement of specific immunoglobulin production in SCID-hu-PBL mice after in vitro priming of human B cells with superantigen.

Authors:  C Mårtensson; P Ifversen; C A Borrebaeck; R Carlsson
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

9.  Induction of B cell apoptosis by TH0, but not TH2, CD4+ T cells.

Authors:  X He; W Zhong; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Humoral immune responses in CD40 ligand-deficient mice.

Authors:  B R Renshaw; W C Fanslow; R J Armitage; K A Campbell; D Liggitt; B Wright; B L Davison; C R Maliszewski
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.